Powder: -20°C for 3 years | In solvent: -80°C for 1 year
XmAb 5592 is a humanized, Fc-engineered antibody targeting HM1.24 with improved affinity for both FcγRIIIa and FcγRIIa receptors. It enhances lysis of HM1.24-specific multiple myeloma (MM) cells through both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in vitro [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | XmAb 5592 is a humanized, Fc-engineered antibody targeting HM1.24 with improved affinity for both FcγRIIIa and FcγRIIa receptors. It enhances lysis of HM1.24-specific multiple myeloma (MM) cells through both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in vitro [1]. |
In vitro | XmAb 5592, within a concentration range of 0-1000 ng/mL, enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against multiple myeloma (MM) cells. Compared to an IgG1 analogue, XmAb 5592 significantly increases ADCC across all cell lines within the 5-27 ng/mL range and also augments macrophage-mediated antibody-dependent cellular phagocytosis (ADCP) [1]. At 0-10000 ng/mL, XmAb 5592 induces potent MM cell lysis via degranulation of NK cells, even in the presence of bone marrow stromal cells (BMSCs) [1]. |
In vivo | XmAb 5592 (0.3-9 mg/kg; i.p.; twice weekly, 7 doses each; RPMI8226 tumor-bearing SCID mice) inhibited tumor growth in mice with human MM xenografts through an FcγR-dependent mechanism [1]. |
Molecular Weight | N/A |
CAS No. | 1221901-33-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
XmAb 5592 1221901-33-2 inhibitor inhibit